Compare Lithium Americas Corp (LAC) vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lithium Americas Corp vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) — how do they compare? Lithium Americas Corp trades at $2.35 (market cap $850.38M), while Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $18.73 (market cap $58.74B). The key difference: Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) is far larger — about 69.1× Lithium Americas Corp's market cap, and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) pays a 3.33% dividend while Lithium Americas Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Lithium Americas Corp for 27 Days and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) for 1 Days on average.
| LAC | TAK | |
|---|---|---|
Market Cap | $850.38M | $58.74B |
Volume | 8,804,637 | 3,110,994 |
Sector | Basic Materials | Health |
52-Week High | $10.05 | $19.05 |
52-Week Low | $2.35 | $13.23 |
Typical Hold Time | 27 Days | 1 Days |
Enterprise Value | $1.19B | $86.65B |
Dividend Yield | — | 3.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lithium Americas (LAC) trades at $2.36, down 2.07% with a bearish technical signal despite bullish oscillators. The company shows negative profitability with ROE at -9.56% and ROA at -3.99%, though it has beaten EPS estimates in recent quarters. Analyst consensus is mixed with 47% buy ratings and a $4.00 price target, representing 69% upside potential. Recent news highlights construction progress at Thacker Pass and a $175 million financing round to strengthen the balance sheet.
LAC presents a high-risk, high-reward opportunity as it transitions from development to execution phase. The stock trades below book value (P/B 0.6) but faces significant execution risks and negative cash flow from operations. Upside depends on successful lithium production ramp-up and favorable lithium pricing, while downside risks include project delays and commodity price volatility.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lithium Americas Corp
Lithium Americas is a resource company focused on developing the Thacker Pass project in Nevada, the largest known lithium resource in the US. It aims to become a major supplier for the electric vehicle battery market.
Read more on LAC →About Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.
Read more on TAK →
